PRL-8-53 10mg

PRL-8-53 is a nootropic compound that was first synthesized in the 1970s by Nikolaus Hansl at Creighton University. Its full chemical name is methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate, and it is classified as a substituted phenethylamine. The exact mechanism of action for PRL-8-53 remains largely unclear. However, it is believed to exhibit cholinergic properties, enhancing the activity of acetylcholine, a neurotransmitter crucial for learning and memory. Additionally, PRL-8-53 may increase dopamine levels, which are associated with motivation and cognitive function, while potentially inhibiting serotonin production, which could affect mood and anxiety levels. The compound has been evaluated in limited studies, with the most notable being a 1978 clinical trial involving 47 healthy adults. Participants who received a 5 mg dose of PRL-8-53 showed improved recall in verbal memory tests compared to those given a placebo. Specifically, significant improvements were noted in individuals who initially performed poorly on the memory tasks